Market Place
Sourcing Support
Vaxxas Licenses Next-Gen RSV Vaccine from NIH
28 Oct 2024 //
BUSINESSWIRE
Vaxxas Starts Phase I Trial Of H7N9 Vaccine Using HD-MAP Technology
11 Sep 2024 //
BUSINESSWIRE
Vaxxas Announces and Publishes Successful Phase I Clinical Trial for Measles
26 Nov 2023 //
BUSINESSWIRE
Australia-Korea joint devp agreement for needle-free of typhoid vaccine
29 Aug 2023 //
BIOSPECTRUM ASIA
Vaxxas Awarded US$3.67 million from global charitable foundation
23 Aug 2023 //
BUSINESSWIRE
Vaxxas opens manufacturing facility for needle-free vaccine patch
19 Jun 2023 //
PHARMAFILE
Vaxxas Opens World-Class MFG Facility To Produce Needle-Free Vaccine Patch
17 Jun 2023 //
BUSINESSWIRE
Vaxxas Announces Results from PI Study of First Needle-Free COVID-19 Vaccine
05 Jun 2023 //
BUSINESSWIRE
Vaxxas Appoints Rochelle Chaiken, M.D., as Chief Medical Officer
05 Jun 2023 //
BUSINESSWIRE
Vaxxas Initiates Phase I Study of First Needle-Free IIV4 Delivered Using HD-MAP
10 Feb 2023 //
BUSINESSWIRE
Vaxxas raises $23M to fund needle-free COVID-19 vaccine trial
06 Dec 2022 //
FIERCEPHARMA
Vaxxas Appoints Doug Cubbin as Chief Financial Officer
01 Dec 2022 //
BUSINESSWIRE
First needle-free COVID-19 vaccine patch
09 Nov 2022 //
EUROPEANPHARMACEUTICALREVIEW
Vaxxas Announces Initiation of Ph I Clinical Study of First Needle-Free COVID-19
08 Nov 2022 //
BUSINESSWIRE
Vaxxas to scale up its vaccine skin patch facility
28 Sep 2022 //
LABONLINE
Vaxxas receives $8.2 million grant to support manufacturing scale-up
20 Sep 2022 //
BUSINESSWIRE
Vaxxas Announces Appointment of Scott Fry Ph.D. as Chief Operating Officer
20 Apr 2022 //
BUSINESSWIRE
Vaxxas Appoints Dan Devine as CBO and General Counsel
13 Apr 2022 //
BUSINESSWIRE
Vaxxas Licenses HexaPro Spike Glycoprotein for Needle-Free Vaccine Patches
23 Mar 2022 //
BUSINESSWIRE
A COVID-19 vaccine in a patch rivals shots in mice
29 Oct 2021 //
FIERCEBIOTECH
Vaxxas Announces $22 M Award from U.S. Government to Advance Vaxxas
05 Oct 2020 //
BUSINESSWIRE
Vaxxas Announces That MSD Exercises Option to Apply Novel Immune System
28 May 2020 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.